AbbVie Inc. (ABBV)

NYQ – Real Time Price. Currency in USD

253.35

+10.21 (4.20%)

At close: Jun 26, 2026, 4:06 PM EDT

252.98

-0.37 (-0.15%)

After-hours: Jun 26, 2026, 7:59 PM EDT

16.06.2026

AbbVie: Maintaining My Strong Buy Rating After Label Expansion

AbbVie maintains strong momentum in immunology, with Skyrizi and Rinvoq offsetting Humira declines and driving double-digit revenue growth. I reaffirm a 'Strong Buy' rating, supported by expanding indications for Skyrizi in Crohn's Disease and Rinvoq in alopecia areata and vitiligo. Skyrizi's subcutaneous induction for Crohn's Disease, validated by phase 3 AFFIRM data, targets further market share and revenue acceleration.

16.06.2026

This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV | ABBV Price Prediction) just got a lot easier to answer.

16.06.2026

AbbVie Stock Will Hit $300 on This Date

AbbVie (NYSE:ABBV | ABBV Price Prediction) has quietly become one of healthcare's most underrated growth stories.

16.06.2026

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

16.06.2026

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

SKINVIVE by JUVÉDERM® is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by "tech-neck.1" This is the second FDA-approved indication for SKINVIVE by JUVÉDERM®, which has been approved since 2023 to improve skin smoothness of the cheeks in adults.1 IRVINE, Calif., June 16, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults over the age of 21.1 With this approval, SKINVIVE by JUVÉDERM® is the first and only hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture, leading to an improved neck appearance.1 Neck wrinkles may develop due to natural aging, sun damage, weight loss, or "tech-neck" caused by the head-down position used for phones, tablets, and books.1 SKINVIVE by JUVÉDERM® reduces neck lines formed by tech-neck by helping the skin retain its natural moisture, softness, and smoothness.1 Treatment with SKINVIVE by JUVÉDERM® is minimally invasive with little to no downtime and is administered using an ultrafine needle or cannula.

12.06.2026

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.

12.06.2026

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

The company is expanding both approved and pipeline therapies. New indications could expand the market for existing drugs.

Videos

01.05.2026

Negative

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

13.01.2026

Positive

AbbVie reaches 3-year deal with White House to lower drug prices

17.12.2025

Neutral

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

14.11.2025

Positive

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
ABBV	Citigroup	Neutral	undefined >> $205	May 14th 2025
ABBV	Cantor Fitzgerald	Overweight	undefined >> $210	April 22nd 2025
ABBV	Daiwa Securities	Neutral	undefined >> $180	December 5th 2024
ABBV	Leerink Partners	Outperform	undefined >> $206	November 22nd 2024
ABBV	Wolfe Research	Outperform	undefined >> $205	November 15th 2024
ABBV	Argus	Buy	undefined >> undefined	November 4th 2024
ABBV	Bernstein	Market Perform	undefined >> $203	October 17th 2024
ABBV	HSBC Securities	Buy	undefined >> $185	June 5th 2024

Press releases

16.06.2026

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

12.06.2026

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden.

10.06.2026

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

The agency's letter cited manufacturing-related items and raised no safety or efficacy concerns. Werschler, a Spokane dermatologist who has served as a clinical trial investigator in dermatology and aesthetic medicine, explains how a Complete Response Letter functions and what a serotype E toxin could add to the category.

08.06.2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Data being presented, including six oral presentations, reinforce AbbVie's leadership and commitment to ongoing research to improve outcomes for people living with blood cancers NORTH CHICAGO, Ill., June 8, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL).

AbbVie Inc. (ABBV)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AbbVie Inc. (ABBV)

AbbVie: Maintaining My Strong Buy Rating After Label Expansion